148 related articles for article (PubMed ID: 29074542)
1. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation.
Charron CE; Russell P; Ito K; Lea S; Kizawa Y; Brindley C; Singh D
Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074542
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease.
Armstrong J; Harbron C; Lea S; Booth G; Cadden P; Wreggett KA; Singh D
J Pharmacol Exp Ther; 2011 Sep; 338(3):732-40. PubMed ID: 21610141
[TBL] [Abstract][Full Text] [Related]
3. Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells.
Higham A; Karur P; Jackson N; Cunoosamy DM; Jansson P; Singh D
Int J Chron Obstruct Pulmon Dis; 2018; 13():1279-1288. PubMed ID: 29719383
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients.
Singh D; Smyth L; Borrill Z; Sweeney L; Tal-Singer R
J Clin Pharmacol; 2010 Jan; 50(1):94-100. PubMed ID: 19880675
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor.
Lea S; Harbron C; Khan N; Booth G; Armstrong J; Singh D
Br J Clin Pharmacol; 2015 May; 79(5):756-66. PubMed ID: 25358442
[TBL] [Abstract][Full Text] [Related]
6. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD.
Pascoe S; Costa M; Marks-Konczalik J; McKie E; Yang S; Scherbovsky PS
Respir Med; 2017 Sep; 130():20-26. PubMed ID: 29206629
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism.
Maneechotesuwan K; Kasetsinsombat K; Wongkajornsilp A; Barnes PJ
Respir Res; 2016 Aug; 17(1):104. PubMed ID: 27557561
[TBL] [Abstract][Full Text] [Related]
8. Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD.
Khorasani N; Baker J; Johnson M; Chung KF; Bhavsar PK
Int J Chron Obstruct Pulmon Dis; 2015; 10():283-91. PubMed ID: 25678784
[TBL] [Abstract][Full Text] [Related]
9. Bronchial epithelial cells produce CXCL1 in response to LPS and TNFα: A potential role in the pathogenesis of COPD.
Inui T; Watanabe M; Nakamoto K; Sada M; Hirata A; Nakamura M; Honda K; Ogawa Y; Takata S; Yokoyama T; Saraya T; Kurai D; Wada H; Ishii H; Takizawa H
Exp Lung Res; 2018 Sep; 44(7):323-331. PubMed ID: 30676127
[TBL] [Abstract][Full Text] [Related]
10. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.
Patel NR; Cunoosamy DM; Fagerås M; Taib Z; Asimus S; Hegelund-Myrbäck T; Lundin S; Pardali K; Kurian N; Ersdal E; Kristensson C; Korsback K; Palmér R; Brown MN; Greenaway S; Siew L; Clarke GW; Rennard SI; Make BJ; Wise RA; Jansson P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1009-1019. PubMed ID: 29628759
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
Watz H; Barnacle H; Hartley BF; Chan R
Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages.
Ratcliffe MJ; Dougall IG
BMC Pharmacol Toxicol; 2012 Nov; 13():15. PubMed ID: 23148608
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Single/Repeated Doses of Acumapimod (BCT197) to Treat Acute Exacerbations of COPD.
Strâmbu IR; Kobalava ZD; Magnusson BP; MacKinnon A; Parkin JM
COPD; 2019 Dec; 16(5-6):344-353. PubMed ID: 31682162
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
15. Epithelial cell senescence impairs repair process and exacerbates inflammation after airway injury.
Zhou F; Onizawa S; Nagai A; Aoshiba K
Respir Res; 2011 Jun; 12(1):78. PubMed ID: 21663649
[TBL] [Abstract][Full Text] [Related]
16. Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs.
Gaffey K; Reynolds S; Plumb J; Kaur M; Singh D
Eur Respir J; 2013 Jul; 42(1):28-41. PubMed ID: 23060629
[TBL] [Abstract][Full Text] [Related]
17. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
Devereux G; Cotton S; Barnes P; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; McCormack K; McPherson G; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Trials; 2015 Jun; 16():267. PubMed ID: 26058585
[TBL] [Abstract][Full Text] [Related]
18. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
Fisk M; Cheriyan J; Mohan D; Forman J; Mäki-Petäjä KM; McEniery CM; Fuld J; Rudd JHF; Hopkinson NS; Lomas DA; Cockcroft JR; Tal-Singer R; Polkey MI; Wilkinson IB
PLoS One; 2018; 13(3):e0194197. PubMed ID: 29566026
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
[TBL] [Abstract][Full Text] [Related]
20. The role of MAPK and Nrf2 pathways in ketanserin-elicited attenuation of cigarette smoke-induced IL-8 production in human bronchial epithelial cells.
Lau WK; Chan SC; Law AC; Ip MS; Mak JC
Toxicol Sci; 2012 Feb; 125(2):569-77. PubMed ID: 22048642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
